Growth Of Specialty Pharma Draws Generics Litigation

Law360, New York (December 3, 2007, 12:00 AM EST) -- As specialty pharmaceutical companies expand their foothold in the pharmaceutical arena, their drugs for niche markets are becoming much more susceptible to patent litigation with aggressive generics companies.

Specialty firms pick up drugs in the late stages that have often been abandoned by bigger drug companies that decide the costs of bringing the drug to market is no longer worth the investment. While drugs that generate under $200 million in annual sales may not be worth the time for a Pfizer or a GlaxoSmithKline, they can...
To view the full article, register now.